Steve Elms - Jun 5, 2025 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
Director
Signature
/s/ Robert Yang, Attorney-in-Fact
Stock symbol
ELEV
Transactions as of
Jun 5, 2025
Transactions value $
$0
Form type
4
Date filed
6/9/2025, 04:20 PM
Previous filing
Feb 21, 2025
Next filing
Jun 16, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
ELMS STEVE Director C/O AISLING CAPITAL MANAGEMENT LP, 489 FIFTH AVENUE, 10TH FLOOR, NEW YORK /s/ Robert Yang, Attorney-in-Fact 2025-06-09 0001250195

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELEV Stock Option (Right to Buy) Award $0 +35K $0.00 35K Jun 5, 2025 Common Stock 35K $0.31 See footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
F2 This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued.